Custom brain exercises show promise for schizophrenia thinking skills
NCT ID NCT04554121
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether personalizing cognitive training based on a person's early auditory processing ability improves thinking and daily function in schizophrenia. 194 adults with schizophrenia or schizoaffective disorder were assigned to either a tailored program (Brain Basics) or standard cognitive training (Brain Training). The goal was to see if matching the exercises to each person's auditory strengths and weaknesses leads to better outcomes in verbal learning and functional capacity.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Cognitive remediation therapy (computer-based brain exercises plus group discussions)
- What this could lead to
- If successful, this approach could lead to more effective cognitive training for people with schizophrenia, improving memory and daily living skills.
- What could go wrong
- This is a completed study, but the intervention is behavioral and effects may be modest. Results may not apply to all patients or settings.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
194 people
The number who actually took part.
- Started
-
Dec 2020
- Finished
-
Dec 2025
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 68 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * A primary DSM-5 diagnosis of schizophrenia or schizoaffective disorder * Psychiatrically stable, as defined by no changes in psychotropic medication or psychiatric hospitalization in the most recent 21 days * English-speaking Exclusion Criteria: * Indications of Intellectual Disability as documented in medical history or measured by \< 70 premorbid Full Scale IQ * Documented auditory disorder or known visual impairment; presence of neurological conditions that are impacting brain and cognitive functioning * Unremitted substance dependence within the past six months * Participation in cognitive remediation in the 24 months prior
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Schizoaffective disorder are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Heights Hill Clinic
Brooklyn, New York, 11217, United States
-
Institute for Community Living
Brooklyn, New York, 11207, United States
-
Laurel House
Stamford, Connecticut, 06902, United States
-
Manhattan Psychiatric Center 125th Street Clinic
New York, New York, 10027, United States
-
Mapleton Mental Health Services
Brooklyn, New York, 11230, United States
-
Pibly Residential Programs Inc.
The Bronx, New York, 10461, United States
-
Rockland Psychiatric Center
Orangeburg, New York, 10962, United States
-
The Bridge, Inc.
New York, New York, 10025, United States
-
Williamsburg Clinic
Brooklyn, New York, 11206, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Scientists probe brain's reward system in mental illness
- New schizophrenia drug targets brain glutamate, not dopamine
- New drug candidate takes aim at schizophrenia symptoms
- New schizophrenia drug goes Head-to-Head with standard antipsychotics in Long-Term trial
- Five-Year safety check for experimental schizophrenia drug
- A shot every few weeks? new drug tested for schizophrenia